| NCT ID | NCT05926219 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Oregon |
| Condition | Aging |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2017-11-06 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 24 participants in total. It began in 2017-11-06 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is investigating changes to the proteins in skeletal muscle that contribute to reduced muscle size and muscle function that occurs with aging.
Eligibility Criteria
Inclusion Criteria: * Adults between the ages 18-35 or 65-80 years * Healthy by self-report * Willing to participate in all aspects of the study design including muscle biopsy, unilateral exercise, and physical activity monitoring * Fluent in English (due to lack of translation services, it is not practical to conduct the study using a language other than English). Exclusion Criteria: * Orthopaedic limitation (severe knee osteoarthritis, prior joint replacement, etc.). * Volunteer has dementia or related mental issues that potentially put the subject at risk as determined by prior diagnosis. * Volunteer has known untreated endocrine disease (hypo/hyper thyroidism, Addison's Disease or Cushing's syndrome, etc.) * Volunteer has untreated/poorly-controlled hypertension (stage 2, per American College of Cardiology \[\>140/90 mmHg\]). * Volunteer has significant heart, liver, kidney or respiratory disease. * Volunteer has diabetes (insulin dependent or non-insulin dependent). * Volunteer has known coagulopathies. * Volunteer has taken anabolic steroids in the prior six months. * Volunteer has received treatment for cancer (other than effective Mohs Surgery for successful removal of basal cell or squamous cell carcinomas) * Unexpected weight loss \>5kg is last 12 months * Volunteer is an active smoker or quit within the last year. * Volunteer has known current alcohol or drug use disorder (AUD; defined as binge drinking of \>4 days in the last month. Binge drinking is \>5 drinks for men and \>4 drinks for women, per occasion). Or, if a volunteer reports drinking in excess of "low risk" per NIAAA (\>7 drinks/week for men and \>3 drinks/day for women and \>14 drinks/week and \>4 drinks/day). * Volunteer has a diagnosed neuromuscular disorder. * Volunteer has allergy to lidocaine.
Contact & Investigator
Damien M Callahan, Ph.D.
PRINCIPAL INVESTIGATOR
University of Oregon
Frequently Asked Questions
Who can join the NCT05926219 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Aging. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05926219 currently recruiting?
Yes, NCT05926219 is actively recruiting participants. Contact the research team at damienc@uoregon.edu for enrollment information.
Where is the NCT05926219 trial being conducted?
This trial is being conducted at Eugene, United States.
Who is sponsoring the NCT05926219 clinical trial?
NCT05926219 is sponsored by University of Oregon. The principal investigator is Damien M Callahan, Ph.D. at University of Oregon. The trial plans to enroll 24 participants.